Cargando…

Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction

AIMS: Congestive heart failure (CHF) and impaired renal function are two often co‐existing medical conditions and associated with adverse cardiovascular outcome. The aim of the current study was to assess renal and intraglomerular haemodynamics by constant infusion input clearance technique in subje...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Susanne, Bosch, Agnes, Kolwelter, Julie, Striepe, Kristina, Kannenkeril, Dennis, Schuster, Tizia, Ott, Christian, Achenbach, Stephan, Schmieder, Roland E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006684/ https://www.ncbi.nlm.nih.gov/pubmed/33559346 http://dx.doi.org/10.1002/ehf2.13257

Ejemplares similares

Is vascular remodelling in patients with chronic heart failure exaggerated?
por: Pietschner, Robert, et al.
Publicado: (2022)

Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study
por: Kolwelter, Julie, et al.
Publicado: (2022)

Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure
por: Bosch, Agnes, et al.
Publicado: (2023)

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
por: Ott, Christian, et al.
Publicado: (2021)

Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
por: Pietschner, R., et al.
Publicado: (2021)

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
por: Kolwelter, Julie, et al.
Publicado: (2021)

Determinants of arterial stiffness in patients with type 2 diabetes mellitus: a cross sectional analysis
por: Staef, Mawadah, et al.
Publicado: (2023)

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
por: Bosch, Agnes, et al.
Publicado: (2019)

The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial
por: Kolwelter, Julie, et al.
Publicado: (2022)

Hypertrophic remodelling of retinal arterioles in patients with congestive heart failure
por: Jung, Susanne, et al.
Publicado: (2021)

Early vascular parameters in the micro- and macrocirculation in type 2 diabetes
por: Kannenkeril, Dennis, et al.
Publicado: (2018)

Myocardial infarction with a preserved ejection fraction—the impaired function of the cardio-renal baroreflex
por: Pickny, Lisa, et al.
Publicado: (2023)

Retinal neurodegeneration in patients with end-stage renal disease assessed by spectral-domain optical coherence tomography
por: Jung, Susanne, et al.
Publicado: (2020)

Resting and exercise haemodynamic characteristics of patients with advanced heart failure and preserved ejection fraction
por: Deis, T., et al.
Publicado: (2021)

Clinical and Haemodynamic Effects of Arteriovenous Shunts in Patients with Heart Failure with Preserved Ejection Fraction
por: Soliman, Medhat, et al.
Publicado: (2022)

Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial( )
por: Dachs, Theresa Marie, et al.
Publicado: (2022)

Intraglomerular micrometastasis of squamous cell carcinoma
por: Sasaki, Kotaro, et al.
Publicado: (2012)

Identification of physiologic treatment targets with favourable haemodynamic consequences in heart failure with preserved ejection fraction
por: Kaye, David M., et al.
Publicado: (2020)

Comparison of haemodynamic response to muscle reflex in heart failure with reduced vs. preserved ejection fraction
por: Moriwaki, Keishi, et al.
Publicado: (2021)

Exercise haemodynamics in heart failure with preserved ejection fraction: a systematic review and meta‐analysis
por: Baratto, Claudia, et al.
Publicado: (2022)

Haemodynamic validation of the three‐step HFA‐PEFF algorithm to diagnose heart failure with preserved ejection fraction
por: Lanzarone, Ettore, et al.
Publicado: (2023)

A renal transplant recipient with intraglomerular Candida albicans
por: Dickson, Zara, et al.
Publicado: (2009)

Retinal Capillary Rarefaction in Patients with Type 2 Diabetes Mellitus
por: Jumar, Agnes, et al.
Publicado: (2016)

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
por: Ott, Christian, et al.
Publicado: (2017)

Persistent atrial fibrillation in heart failure with preserved ejection fraction: Prognostic relevance and association with clinical, imaging and invasive haemodynamic parameters
por: Schönbauer, Robert, et al.
Publicado: (2019)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
por: Karg, M. V., et al.
Publicado: (2018)

Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers
por: Gessner, Arne, et al.
Publicado: (2022)

The kinocardiograph for assessment of changes in haemodynamic load in patients with chronic heart failure with reduced ejection fraction
por: Herkert, Cyrille, et al.
Publicado: (2021)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020)

Managing heart failure with preserved ejection fraction
por: Davidson, Alexander, et al.
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Comorbidities in heart failure with preserved ejection fraction
por: Deichl, Andrea, et al.
Publicado: (2022)

On-Center/Inhibitory-Surround Decorrelation via Intraglomerular Inhibition in the Olfactory Bulb Glomerular Layer
por: Cleland, Thomas A., et al.
Publicado: (2012)

Task-specific roles of local interneurons for inter- and intraglomerular signaling in the insect antennal lobe
por: Fusca, Debora, et al.
Publicado: (2021)

Visualizing diastolic failure: Non-invasive imaging-biomarkers in patients with heart failure with preserved ejection fraction
por: Schulz, Alexander, et al.
Publicado: (2022)

Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction
por: Zordoky, Beshay N., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_a3jumva8or85t0b2pns2v9qb19